Cambridge headquartered AstraZeneca and its global biologics R & D arm MedImmune, plan to develop new therapies for respiratory disease through a five-year collaboration with Munich-based Ethris GmbH.
The Cambridge UK duo will pay Ethris €25 million upfront, plus research funding; Ethris is also eligible for future R & D milestones, including sales-related royalties on commercialisation.
Gaithersburg-based immunotherapy company Altimmune Inc. announced Tuesday it plans to expand into a new headquarters, but it’s not going far.
Altimmune (NASDAQ: ALT) officials said they plan to relocate existing employees — as well as new employees acquired as a result of its acquisition of Annapolis biodefense company PharmAthene Inc. — to a 14,000-square-foot space at 910 Clopper Road. The company is currently based at 19 Firstfield Road, less than a mile away.
Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest.
As a global key player in yeasts and fermentation, Lesaffre designs, manufactures and markets innovative solutions for Baking, Food taste & pleasure, Health care and Biotechnology. This new investment is perfectly in line with Lesaffre’s ongoing expansion strategy in nutrition and health. In 2015, Lesaffre had already announced the investment in Gnosis, an Italian company specialized in ingredients for the pharmaceutical, nutraceutical, cosmetic and veterinary industries.
Deadline Extended to August 24, 2017! Submit your proposal today
There’s still time to submit your proposal for the “Make Your Medical Device Pitch for Kids!” competition. Deadline extended to Thursday, August 24, 2017 at midnight PDT.
Up to six prizes totaling $250,000 will be awarded to the winning presentations at the nation’s leading pediatric innovation symposium on Sunday, September 24, 2017. Are you registered for the Symposium?
Join us for the 5th Annual Pediatric Device Innovation Symposium in San Jose, CA – one day before The MedTech Conference powered by AdvaMed.
It’s a results-driven day that brings together medical device innovators, investors, researchers, clinicians, and policy makers to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere.
Innovation is a principal driver of U.S. economic growth. In 2016, the U.S. spent an estimated $514 billion on research and development — more than any other country in the world — helping the nation rank No. 4 on the Global Innovation Index. According to the results of the ranking, knowledge and technology outputs are America’s particular strengths.
But certain states are due more credit than others for America’s dominance in the tech era. These states continue to foster innovation through investments in education, research and business creation, especially in highly specialized industries.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced, following a four-day bench trial, that the United States District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. and its subsidiary infringed U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930 by submitting to the FDA an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Oxtellar XR® before the expiration of Supernus’ patents. The District Court ruling also confirmed the validity of U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930.
The National Institute of Standards and Technology on Wednesday published new guidance on how to strengthen passwords. Why now? Research shows that the de facto standard practice of requiring users to include a mix of uppercase and lowercase letters, numbers and at least one symbol, is more trouble than it’s worth.
“Analyses of breached password databases reveal that the benefit of such rules is not nearly as significant as initially thought,” NIST explained. “The impact on usability and memorability is severe.”
Maryland gained 800 jobs in July and unemployment fell for the third consecutive month.
The private sector added 11,500 positions while government positions decreased by 10,700, according to preliminary data released Friday by the U.S. Department of Labor. Maryland’s unemployment rate dropped to 4 percent in July from 4.1 percent.
Senseonics Holdings, Inc. (NYSE MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of its previously announced underwritten public offering. Senseonics is offering 11,637,500 shares of its common stock, par value $0.001 per share, at a price to the public of $2.15 per share. In connection with the offering, Senseonics has also granted the underwriter a 30-day option to purchase up to an additional 1,745,625 shares of common stock offered in the public offering to cover over-allotments, if any. Senseonics intends to use the net proceeds from the offering primarily to begin commercialization of Eversense in the United States, if approved, to fund continued research and development of future configurations of Eversense, and for working capital and general corporate purposes. The offering is expected to close on August 23, 2017, subject to the satisfaction or waiver of customary closing conditions.
Venture capital spending continues to lag behind the record activity of recent years, but startups needn’t worry; industry analysts say there’s still billions in dealmaking still to be done.
Nationally, VC firms invested roughly $38 billion in startups and other early-stage companies during the first two quarters this year, down 10 percent from the $42 billion recorded during the same span in 2016 and off about $2 billion from 2015, according to data collected by Pitchbook and the National Venture Capital Association.
